Atrial Fibrillation Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have a type of irregular heart rhythm called atrial fibrillation (AF) — either one that comes and goes, or one that is ongoing — confirmed by a heart tracing test (ECG) or a monitoring device within the past 24 months, with the episode lasting at least 30 seconds.
• People whose treating doctor has determined they are a suitable candidate for an ablation procedure based on current medical guidelines for AF.
• People who have been taking blood-thinning medication (either warfarin-type or a newer type called a NOAC) continuously for at least 4 weeks before the ablation, OR who have had a heart imaging test (TEE or CT scan) within 48 hours before the ablation confirming no blood clots in the heart.
• People aged 18 or older at the time of signing the consent form.
• People who have read, understood, and signed the consent form to participate.

Who may not be able to join:

• People who have previously had an ablation procedure or surgery involving the left side of the heart (left atrium).
• People whose AF has been continuous for longer than 12 months.
• People whose AF was caused by a temporary or reversible condition.
• People who currently have a blood clot inside their heart.
• People who have previously had narrowing or stenting of the pulmonary veins (blood vessels connecting the lungs to the heart).
• People who already have paralysis on one side of their diaphragm (the main breathing muscle).
• People with a known allergy or medical reason to avoid blood-thinning medications or contrast dye used in imaging.
• People who have had surgery on their mitral valve (a valve in the heart).
• People with significant disease affecting the mitral valve.
• People who had a heart attack within the three months before signing consent.
• People currently taking three blood-thinning medications at the same time.
• People who have had heart surgery in the past three months, or who have heart surgery or a TAVI procedure (a type of heart valve procedure) already planned.
• People with major structural heart defects present from birth.
• People with severe heart failure (classified as NYHA class III or IV — meaning significant limitation of physical activity or symptoms even at rest).
• People whose heart's pumping function is significantly reduced (ejection fraction below 35%).
• People diagnosed with a thickened heart muscle condition called hypertrophic cardiomyopathy (with a wall thickness over 1.7 cm).
• People with severe long-term kidney disease (confirm with trial site for exact measurement).
• People with uncontrolled overactive thyroid.
• People who have had a stroke or mini-stroke (TIA) within the three months before signing consent.
• People with an active infection anywhere in the body.
• People with a history of a condition called cryoglobulinemia (a blood disorder).
• People diagnosed with a condition called cardiac amyloidosis (a disease where abnormal proteins build up in the heart).
• People who are currently pregnant.
• People whose treating doctor estimates their life expectancy to be less than one year.
• People already enrolled in another clinical study that could affect the results of this trial.
• People who are unable or unwilling to follow the study requirements and attend follow-up visits.

Important: Always verify eligibility with the trial site directly before applying.